Search results
Showing 931 to 945 of 1773 results for patient safety
Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.
Transcranial direct current stimulation (tDCS) for depression (HTG382)
Evidence-based recommendations on transcranial direct current stimulation (tDCS) for depression. This involves electrical stimulation of the brain by applying a weak direct current to the scalp.
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.
Evidence standards framework for digital health technologies (ECD7)
This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England
Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules (HTG416)
Evidence-based recommendations on ultrasound-guided percutaneous radiofrequency ablation for treating benign thyroid nodules in adults. This involves using heat energy to destroy tissue in the nodules.
The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)
NICE has developed a Medtech Innovation Briefing (MIB) on the RhinoChill intranasal cooling system
Evidence-based recommendations on daridorexant (QUVIVIQ) for treating long-term insomnia in adults.
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies.
Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)
Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults.
This quality standard covers diagnosing, managing and treating rare diseases in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS214Show all sections
Sections for QS214
- Quality statements
- Quality statement 1: Referral for investigation and treatment
- Quality statement 2: Undiagnosed conditions
- Quality statement 3: Information provision
- Quality statement 4: Shared decision making
- Quality statement 5: Named healthcare professional
- Quality statement 6: Holistic needs assessment
- Quality statement 7: Access to treatment
Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)
Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making
Mini/micro screw implantation for orthodontic anchorage (HTG152)
Evidence-based recommendations on mini/micro screw implantation for orthodontic anchorage. This involves inserting small screws into the jaw bone to create anchors that support tooth realignment.
View recommendations for HTG152Show all sections
Sections for HTG152
Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)
Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making